GeneTex
United States (US)

RAIDD peptide

Cat No. GTX28461

Application Blocking
Species Human
APPLICATION

Application Note

The peptide is used for blocking the activity of RAIDD (CT) (GTX28425). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity in Western blotting.
PROPERTIES

Form

Liquid

Buffer

PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide

Storage

Store the peptide at -20˚C, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Casp2 And Ripk1 Domain Containing Adaptor With Death Domain,Mrt34,Raidd,Cradd

Background

Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNFfamily through their death domain (DD) containing receptors, TNFR1 and Fas. The death signals are transduced by a group of DD containing adapter molecules. A novel cell death adapter was recently identified by two independent groups and designated RAIDD (RIP associated ICH1/CED3 homologous protein with DD) and CRADD (caspase and RIP adapter with DD). RAIDD contains a DD and a CARD (for caspase recruitment domain) which interact with RIP and caspase, respectively, to transduce death signals. RAIDD is constitutively expressed in many tissues and mediates apoptosis caused by Fas and TNFR1.

Research Area

Package List Price ($)
$ 179